Blogs

Package integrity testing is only as reliable as the conditions it's performed under. Temperature swings, pressure changes, and humidity can all shift a result without any real change in the package itself. For quality teams running Container Closure Integrity Testing (CCIT) programs, understanding how environmental conditions affect package integrity testing is essential to trusting the data and staying audit ready.

What Effect Do Temperature and Pressure Have on Package Integrity Results?

Temperature and pressure directly affect how a package behaves during testing, often more than the seal quality itself. A few key effects include:

• Gas expansion and contraction. Warmer conditions expand trapped headspace gas, while cooler conditions contract it. Either can shift the pressure readings a vacuum decay test relies on.
• Material flexing. Plastics and elastomeric seals expand and contract with temperature, which can open or close marginal leak paths that would otherwise stay consistent.
• Altitude and barometric pressure. Testing at different elevations, or even during weather-driven pressure shifts, changes the baseline vacuum level and can produce false readings if the system isn't compensating for it.
• Rapid temperature transitions. Moving a package straight from cold storage into a room-temperature test chamber introduces condensation and thermal stress that can mimic or mask a real leak.

These effects matter because they're independent of the package's actual integrity. A perfectly sealed vial can still fail a poorly controlled test.

How Does the Testing Environment Influence Package Integrity Results?

The testing environment influences results by introducing variability that has nothing to do with the product itself. Humidity, ambient temperature drift, and equipment calibration all shape what a test reports as pass or fail.

Vacuum decay systems measure extremely small pressure changes, often in the millitorr range, so even a modest shift in room temperature during a test cycle can register as a false positive or mask a genuine defect. Humidity affects sensor accuracy and can contribute to condensation inside test chambers. Uncalibrated equipment compounds all of this, since a sensor drifting even slightly changes what counts as a pass threshold. This is why regulatory bodies and standards such as USP <1207> emphasise validated, controlled test environments alongside deterministic test methods. PTI's Vacuum Decay Technology is designed with these requirements in mind, helping manufacturers generate reliable, repeatable data under controlled conditions.

How Can You Ensure Repeatable Results With Vacuum Decay Testing?

You ensure repeatable vacuum decay results by standardising the physical test environment alongside the test parameters themselves. That means controlling temperature, allowing proper equilibration time, and calibrating equipment on a fixed schedule.

Vacuum Decay Technology is a deterministic, non-destructive CCIT method recognized under USP <1207>, making it well suited to repeatable, high-volume testing. PTI's VeriPac® systems are designed to minimize environmental variability while delivering highly sensitive and repeatable leak detection results.

What Are the Best Practices for Controlled Package Integrity Testing?

The best practices for controlled testing centre on treating the environment as part of the test method, not a separate variable. Effective steps include:

• Stabilize samples before testing. Allow packages to equilibrate to chamber temperature fully before running a test cycle.
• Monitor and log chamber conditions. Continuous temperature and humidity logging helps identify drift before it affects results.
• Calibrate on a fixed schedule. Regular calibration against traceable standards keeps sensitivity consistent over time.
• Standardize test protocols. Fixed vacuum levels, dwell times, and sample orientation reduce operator-to-operator variability.
• Qualify the test method to the product. A method validated for one container type or material may not perform the same way on another.

Incorporating deterministic technologies with validated testing protocols further strengthens repeatability and helps support regulatory compliance throughout the product lifecycle.

What's the Key Takeaway on Environmental Conditions and Package Integrity?

Environmental conditions are not background noise in package integrity testing—they are an active part of the result. Temperature, pressure, and humidity can each influence a vacuum decay reading independent of the package's actual seal quality, which is why controlling the test environment is just as important as selecting a validated deterministic test method. PTI's VeriPac® Vacuum Decay Testing systems are engineered to deliver reliable, repeatable, and non-destructive CCIT performance, helping manufacturers meet USP <1207> expectations and maintain confidence in every test result.

Frequently Asked Questions

1. Can temperature changes cause a false leak result in vacuum decay testing?

Yes. Expanding or contracting headspace gas can shift pressure readings enough to register as a leak even when the seal is intact, which is why equilibration time matters.

2. Does humidity affect container closure integrity testing?

It can. Humidity influences sensor accuracy and condensation risk inside test chambers, both of which can distort results if not controlled.

3. How often should test equipment be calibrated for reliable results?

Calibration frequency should follow a fixed, documented schedule based on equipment type and usage, validated against traceable reference standards rather than performed only when a problem is suspected.

Scaling a packaging process from pilot batches to full commercial production is a critical stage where package integrity challenges often become more apparent. A packaging system that demonstrates acceptable performance during pilot-scale production may behave differently when subjected to higher production speeds, longer manufacturing runs, multiple sealing lanes, equipment variability, and routine process fluctuations. As production volume increases, even small process variations can affect seal quality and container closure integrity.

Understanding why these challenges occur—and how deterministic, non-destructive Container Closure Integrity Testing (CCIT) methods such as Vacuum Decay and Airborne Ultrasound can help detect integrity issues early—is essential for manufacturers transitioning from development to commercial production.

What Causes Packaging Failures During Scale-Up Manufacturing?

A process that performs flawlessly with a single operator and one sealing head at pilot scale rarely behaves identically across a multi-lane production line running continuously. Common contributors include:

• Increased line speeds that reduce seal dwell time
• Multiple sealing heads or lanes operating with slight parameter differences
• Tooling wear and thermal drift over long production runs
• Variability in raw material lots (films, trays, pouches)
• Environmental shifts in humidity and temperature across shifts
• Operator and changeover variability at higher throughput

What Challenges Arise When Scaling Up Packaging Processes? 

Pilot runs typically use limited samples and short durations, so they rarely expose the cumulative effects of thermal drift, mechanical fatigue, or multi-cavity variability. As production volume grows, manufacturers face:

• Longer runs where seal bars gradually lose calibration
• Greater sensitivity to raw material variability across larger lot sizes
• Higher stakes for undetected micro-leaks, since defects propagate across thousands of units instead of dozens
• Pressure to increase throughput without compromising seal quality

How Do Equipment and Sealing Variability Contribute to Package Integrity Failures?

Factors Contributing to Seal Defects and Package Integrity Failures

Because these defects can be intermittent and sub-visual, relying on visual inspection or destructive dye-penetration testing alone often lets nonconforming packages reach the market undetected.

How Does Process Qualification with Vacuum Decay and Airborne Ultrasound Improve Reliability?

Deterministic methods produce quantitative, repeatable results, unlike probabilistic methods such as dye ingress or bubble emission, which depend on operator judgment. This makes them well suited to establishing and monitoring a robust seal process during scale-up.

• Vacuum Decay Testing (per ASTM F2338) places a package in a test chamber, draws a vacuum, and measures pressure change over time. A stable pressure indicates an intact seal; any decay signals a leak path, often down to channels as small as 10–50 microns, depending on package format.
• Airborne Ultrasound Testing (ASTM F3004) detects the acoustic signature of turbulent airflow escaping through seal defects while the package is still under normal atmospheric conditions. It is especially effective for flexible pouches and porous or non-porous packaging where visual and dye-based methods struggle.

Both methods can be deployed for offline process qualification and, in many operations, adapted for at-line or in-line monitoring, giving manufacturers real-time visibility into seal quality as production scales.

How Can Manufacturers Improve Packaging Robustness During Scale-Up?

Manufacturers can improve packaging robustness during scale-up by combining sound process development with ongoing process monitoring and objective package integrity evaluation. Rather than relying solely on final validation testing, successful scale-up programs incorporate scientific process characterization and non-destructive integrity testing throughout development and commercial implementation.

Practical strategies include:

• Conducting Design of Experiments (DOE) studies to characterize acceptable operating windows for sealing temperature, pressure, dwell time, and other critical process parameters.
• Qualifying each sealing head, lane, or production station individually to identify equipment-specific variability.
• Incorporating at-line or routine non-destructive Container Closure Integrity Testing (CCIT), where appropriate, to evaluate package performance throughout scale-up.
• Using quantitative integrity test data to establish statistically justified process monitoring and control limits.
• Reassessing package performance following significant changes to tooling, packaging materials, equipment settings, production rates, or manufacturing processes.

By integrating deterministic, non-destructive CCI Technologies with process characterization and statistical monitoring, manufacturers can identify process drift earlier, strengthen packaging robustness, and reduce the risk of recurring integrity failures as production transitions from pilot-scale development to commercial manufacturing. This science-based approach supports process understanding, quality risk management, and lifecycle validation while helping ensure consistent package performance throughout commercial production.

These activities support Quality by Design (QbD) principles by improving process understanding, identifying critical process parameters, and establishing a robust manufacturing process capable of consistently producing packages that meet integrity requirements.

Conclusion

Packaging failures during scale-up are rarely a sign of poor initial design. They're usually a sign that pilot-scale validation didn't account for the variability introduced at production volume. Vacuum decay and airborne ultrasound testing give manufacturers the quantitative, repeatable data needed to qualify sealing processes with confidence and maintain package integrity as production scales.

Frequently Asked Questions

1.What is the difference between vacuum decay and airborne ultrasound testing?

Vacuum decay measures pressure change in a sealed test chamber to detect leaks, while airborne ultrasound detects the acoustic signal of air escaping through a seal defect under normal atmospheric conditions. Both are non-destructive and deterministic.

2. Is vacuum decay testing destructive to the package?

No. Vacuum decay is a non-destructive test, so the same package can be released for use or further testing after evaluation.

3. Which packaging materials work best with airborne ultrasound testing?

Airborne ultrasound is particularly effective for flexible pouches and form-fill-seal packages where seal channels may be too fine for other non-destructive methods to detect reliably.

4. What standards govern package integrity testing in the U.S.?

ASTM F2338 covers vacuum decay testing, and airborne ultrasound methods are increasingly referenced alongside ASTM F3263 for non-destructive seal quality assessment in pharmaceutical and medical device packaging.

Package integrity is a fundamental requirement for sterile pharmaceutical products. When a container closure system fails to maintain its integrity, the consequences range from contamination and potency loss to direct patient harm. FDA expects manufacturers to demonstrate that container closure systems perform as intended throughout the product's shelf life, and to have the data to prove it.

Container closure integrity testing (CCIT) is the primary tool used to establish and verify that assurance. When CCIT programs are absent, poorly validated, or reliant on methods that cannot produce defensible data, FDA inspections frequently result in observations and, in serious cases, warning letters. Understanding the patterns behind those citations helps manufacturers build programs that are both scientifically sound and inspection ready.

What Types of Packaging Integrity Failures Commonly Trigger FDA Observations?

FDA observations related to packaging integrity most often arise when manufacturers cannot demonstrate that their container closure systems reliably maintain sterility. The absence of scientifically sound CCIT, incomplete validation documentation, and inadequate investigation of known defects are recurring themes in inspection reports and warning letters.

Common FDA concerns include:

• Inadequate package integrity verification: No validated method in place to confirm container closure integrity before or after product release.
• Lack of scientifically sound test methods: Reliance on visual inspection or dye ingress testing without sensitivity justification or acceptance criteria.
• Insufficient validation documentation: Studies that lack repeatability data, challenge sample characterization, or defined worst-case conditions.
• Failure to demonstrate lifecycle integrity: No evidence that the packaging system maintains its performance across the full shelf life.
• Poor investigation of packaging defects: Defects identified during production not adequately investigated or documented.
• Inadequate risk assessments: No formal evaluation of packaging failure modes or their potential impact on product quality and patient safety.

What Validation Deficiencies Are Frequently Observed During FDA Inspections?

Validation deficiencies are among the most commonly cited packaging-related issues in FDA inspections. Investigators examine whether manufacturers have adequately established that their chosen CCIT method is fit for purpose—and many programs fall short.

Frequently observed gaps include:

• Incomplete validation studies with no challenge samples or positive controls.
• Lack of sensitivity studies to demonstrate the method can detect relevant defect sizes.
• Failure to establish and justify acceptance criteria.
• Insufficient method repeatability and reproducibility data.
• Reliance on outdated testing approaches without scientific justification.
• No documented rationale for test method selection relative to the packaging system and product.

What Is CCIT Validation?

CCIT validation is the process of demonstrating that a container closure integrity test method is fit for its intended use and can reliably detect relevant package defects under defined operating conditions. A validated CCIT program establishes method performance characteristics such as sensitivity, repeatability, reproducibility, and acceptance criteria using appropriately characterized positive and negative control samples. It provides documented evidence that the method performs consistently and is suitable for evaluating container closure integrity throughout the product lifecycle.

Why Are Probabilistic Testing Methods Considered a Compliance Risk?

Probabilistic testing methods, including visual inspection, dye ingress, and microbial challenge testing, rely on subjective judgment or indirect indicators of package integrity. They produce pass/fail observations rather than quantitative measurements, and their results are highly dependent on operator skill, sample preparation, and environmental conditions.

This variability creates significant compliance exposure. When FDA investigators examine validation data for probabilistic methods, they frequently find limited sensitivity characterization, no defined acceptance criteria, and insufficient repeatability evidence. Deterministic testing methods eliminate these vulnerabilities by generating objective, numerical data that can be trended, validated, and defended in regulatory submissions.

Why Does FDA Prefer Deterministic Testing Methods?

FDA and industry guidance documents, USP <1207> and PDA Technical Report No. 27, categorize deterministic methods as preferred for container closure integrity testing because they generate quantitative, reproducible data that can be scientifically validated. Unlike probabilistic methods, deterministic approaches do not depend on operator interpretation, making them more defensible during inspections and better suited to lifecycle validation programs.

How Does CCIT Vacuum Decay Improve Compliance and Validation Confidence?

Vacuum decay testing is a deterministic, non-destructive test method in which a sealed package is placed inside a test chamber, the chamber is evacuated to a defined vacuum level, and any pressure change over time is measured. A package with a leak path will show a measurable deviation from expected vacuum behavior, producing a quantitative result that is directly tied to the presence or absence of a defect.

From a compliance perspective, Vacuum Decay offers several advantages. Its results are objective and numerical, there is no operator interpretation involved. The method can be fully validated using characterized positive controls at defined defect sizes. It is non-destructive, enabling 100% inspection of production batches. And it is recognized in USP <1207.1> as a preferred deterministic method, providing a strong regulatory foundation for validation submissions and inspection responses.

Vacuum Decay is applicable to a wide range of pharmaceutical packaging formats, including vials, pre-filled syringes, ampoules, and flexible packaging, making it one of the most broadly deployed deterministic testing methods in sterile drug manufacturing.

How Does High Voltage Leak Detection (HVLD) Strengthen Container Closure Integrity Testing?

High Voltage Leak Detection (HVLD) applies a high-voltage electrical field across the external surface of a liquid-filled container. When a defect is present, the conductive liquid product creates a current pathway through the container wall, generating a detectable electrical signal. The method is non-destructive, does not require contact with the product, and produces quantitative results directly correlated to the presence of a breach.

HVLD is particularly effective for liquid-filled vials, cartridges, syringes, and ampoules, product types that are common in injectable sterile drug manufacturing. Its high sensitivity to both conductive and semi-conductive pathways gives it strong detection capability across a range of defect types and sizes.

For compliance purposes, HVLD offers the same core advantages as other deterministic testing methods: objective data, validated sensitivity, and operator-independent results. These characteristics directly address the validation deficiencies most commonly cited during FDA inspections of liquid-filled sterile product lines.

How Can Manufacturers Improve Inspection Readiness for Package Integrity Testing Programs?

Inspection readiness for package integrity testing is built through consistent process discipline, not last-minute preparation. Manufacturers that adopt deterministic testing methods, develop risk-based validation strategies, and maintain complete documentation are significantly better positioned when FDA investigators arrive.

Key best practices include:

• Adopting validated deterministic testing methods appropriate to the packaging format and product.
• Developing risk-based CCIT strategies that address packaging failure modes and their patient safety implications.
• Establishing comprehensive SOPs covering test method operation, acceptance criteria, and out-of-specification procedures.
• Maintaining complete and retrievable validation records, including protocols, reports, and raw data.
• Performing periodic reviews of CCIT performance data to identify trends and support continuous process verification.
• Documenting all personnel training and qualification for CCIT operations.
• Implementing data integrity controls that prevent unauthorized modification and support complete audit trails.

Inspection Readiness Checklist

• Risk-based CCIT strategy established
• Validation protocols documented
• Acceptance criteria justified
• Repeatability studies completed
• Data integrity controls implemented
• Change management procedures maintained
• Personnel training documented
• Periodic reviews conducted

What Are the Key Takeaways for Avoiding Packaging Integrity-Related FDA Observations?

FDA observations related to packaging integrity share a common profile: validation programs that cannot withstand scientific scrutiny, documentation that is incomplete or inaccessible, and testing methods that produce data of limited defensibility. Addressing these vulnerabilities requires deliberate investment in the right technologies and quality infrastructure.

The most important actions manufacturers can take are:

• Replace probabilistic methods with validated deterministic testing methods that generate quantitative, reproducible data.
• Validate thoroughly: Sensitivity studies, repeatability data, and justified acceptance criteria are non-negotiable for inspection readiness.
• Document everything: From instrument qualification to personnel training, the paper trail is the compliance record.
• Apply a lifecycle approach: CCIT is not a one-time qualification. Ongoing monitoring and change control are expected.
• Understand your packaging risk: A formal risk assessment guides technology selection and validation scope.

Conclusion

FDA warning letters related to packaging integrity are preventable. The underlying causes like inadequate validation, reliance on probabilistic methods, and incomplete documentation, are well understood, and the industry has the tools to address them. Deterministic testing methods such as Vacuum Decay, Airborne Ultrasound, and HVLD provide the scientific foundation that modern CCIT programs require. Manufacturers that invest in rigorous validation programs, maintain complete records, and align their CCIT strategies with current regulatory expectations will find that inspection readiness is not a separate exercise, it is simply the output of a well-run quality system.